The study published recently in the Nature Briefing Journal explores using mathematical modeling to address drug development challenges in pulmonary arterial hypertension. Researchers developed a quantitative systems pharmacology (QSP) model in the context of oral treprostinil clinical studies to predict changes in pulmonary vascular resistance and six-minute walk distance by creating a virtual patient population that mirrors clinical trial observations.
The model aims to forecast clinical trial results by simulating different scenarios, including variations in disease severity, dosing regimens, time since diagnosis, and background therapies. By demonstrating the potential to enrich populations based on clinical biomarkers, the research suggests QSP modeling could enhance clinical trial design and increase the likelihood of success in pulmonary arterial hypertension drug development.
Treprostinil is a prostacyclin (PGI2) analogue.
Read more at this link
Citation
Stine, A.E., Parmar, J., Smith, A.K. et al. Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population. npj Syst Biol Appl 11, 9 (2025). https://doi.org/10.1038/s41540-024-00481-y